Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Liabilities from Discontinued Operations (2016)

Historic Liabilities from Discontinued Operations for Protalix BioTherapeutics (PLX) over the last 3 years, with Q2 2016 value amounting to $293000.0.

  • Protalix BioTherapeutics' Liabilities from Discontinued Operations changed N/A to $293000.0 in Q2 2016 from the same period last year, while for Jun 2016 it was $293000.0, marking a year-over-year change of. This contributed to the annual value of $1.6 million for FY2015, which is 9703.2% down from last year.
  • Protalix BioTherapeutics' Liabilities from Discontinued Operations amounted to $293000.0 in Q2 2016.
  • In the past 5 years, Protalix BioTherapeutics' Liabilities from Discontinued Operations ranged from a high of $52.8 million in Q4 2014 and a low of $128000.0 during Q1 2016
  • For the 3-year period, Protalix BioTherapeutics' Liabilities from Discontinued Operations averaged around $13.7 million, with its median value being $930500.0 (2015).
  • Over the last 5 years, Protalix BioTherapeutics' Liabilities from Discontinued Operations had its largest YoY gain of 9703.2% in 2015, and its largest YoY loss of 9703.2% in 2015.
  • Quarter analysis of 3 years shows Protalix BioTherapeutics' Liabilities from Discontinued Operations stood at $52.8 million in 2014, then crashed by 97.03% to $1.6 million in 2015, then crashed by 81.31% to $293000.0 in 2016.
  • Its Liabilities from Discontinued Operations stands at $293000.0 for Q2 2016, versus $128000.0 for Q1 2016 and $1.6 million for Q4 2015.